ThinkstockMannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 diabetes is being hailed…
After markets closed last Friday, MannKind announced that the FDA had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control in adults with diabetes.
ThinkstockThe rise and fall of health care stocks is often hard to grasp, particularly in a world where the health care laws are creating some large potential winners and losers. Many investors guessed that…
ThinkstockThe U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The FDA estimates that 25.8…
Vertex Pharmaceuticals has reported that two Phase 3 studies of its lumacaftor cystic fibrosis drug in combination with its Kalydeco ivacaftor showed positive results. Shares spikes on the news.
ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some health care professionals. Their overuse in some cases has led many of the major…
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
The UBS team highlights six top stocks that are seeing increased prescription volume since the implementation of parts of the Affordable Care Act.
Insmed shares screamed higher on Wednesday. The driver was an SEC filing stating the FDA had granted Arikace breakthrough therapy designation.
The $42.9 billion merger between medical device makers Medtronic and Covidien was officially confirmed early Monday morning. The deal is a so-called tax inversion.
ThinkstockThe U.S. health care system is the most expensive among large developed nations. And it produces the worst results. Medical costs are among the highest portions of Americans’ budgets. But people hardly get what…
MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for diabetes. Afrezza almost certainly will become a blockbuster drug if approved.
ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close up one penny on…
In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on the outcomes.
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in…